000963 华东医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入10,735,7883.12%41,905,70740,623,78337,714,58734,563,301
减:营业总成本9,620,0073.09%37,493,02037,081,91534,568,57031,727,336
    其中:营业成本7,206,5981.84%27,988,54727,461,73225,682,49723,957,371
               财务费用14,61893.49%22,26551,19078,25722,075
               资产减值损失----(41,006)(6,520)(3,822)(16,908)
公允价值变动收益------(13,756)28,469--
投资收益(42,624)-9.62%(129,191)(219,713)(141,560)(96,312)
    其中:对联营企业和合营企业的投资收益(28,249)-24.68%(68,453)(188,391)(115,619)(53,433)
营业利润1,132,2575.61%4,324,7373,452,9273,061,4542,855,714
利润总额1,104,9513.44%4,301,5143,465,9863,031,1242,827,535
减:所得税费用190,967-8.16%807,328619,589498,499488,907
净利润913,9846.25%3,494,1862,846,3972,532,6262,338,628
减:非控股权益(724)-66.56%(17,919)7,53633,41136,996
股东净利润914,7086.06%3,512,1052,838,8612,499,2142,301,631

市场价值指针
每股收益 (元) *0.5225.98%2.0051.6221.4281.315
每股派息 (元) *----0.9300.5800.2900.290
每股净资产 (元) *13.7169.60%13.14511.99710.5929.475
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容